Abstract
Leishmaniasis, a life-threatening tropical disease that is endemic in nearly 100 countries, contributes to millions of deaths each year. However, very few antileishmanial compounds are available in the market and that too possess many drawbacks. Hence, the therapeutic arsenal requires potential and novel anti-leishmanial compounds to treat Leishmaniasis. In the present study, quantitative structure activity relationship (QSAR) model and Pharmacophore model were developed with a set of antileishmanial compounds collected from literature and commercial antileishmanial drugs. A ligand-based pharmacophore model was developed using active compound as template and it was used for searching the purchasable compound dataset of ZINC database for matching compounds. Thirteen novel, readily purchasable compounds were obtained from this approach, which shows good predicted activity, ADME and druglikeness. These compounds can be regarded as potential candidates to be developed as novel antileishmanial drugs with improved activity and reduced side effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Computational Biology and Drug Design
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
